Tirzepatide , a dual GIP/GLP-1 receptor agonist, demonstrated superior efficacy to semaglutide in a landmark head-to-head trial, with patients receiving ZEPBOUND losing an average of 50 pounds over 72 weeks compared with 33 pounds among WEGOVY-treated patients
In the long term, injectables are expected to coexist with orals, with each addressing distinct patient and payer priorities rather than one displacing the other
You can restrict calories in an inflamed body and fight the biology the entire time
March 9, 2026 glofusion2025 Blog, Weight Loss GloFusion Griffin & McDonough, GA The scale stops moving
Persistent nausea, early satiety, bloating, or constipation may lead to reduced treatment satisfaction and contribute to therapy interruption or discontinuation
They share the same active ingredient, semaglutide, but they are different products